Date of Award
Daniel Felix Ritchie School of Engineering and Computer Science, Mechanical and Materials Engineering
Ali N. Azadani
Matt J. Rutherford
Matt H. Gordon
Balloon pulmonary angioplasty (BPA), Food and Drug Administration (FDA), Surgical pulmonary valve replacement (SPVR), Transcatheter pulmonary valve replacement (TPVR)
Currently, transcatheter pulmonary valve replacement (TPVR) is a well-established alternative for surgical pulmonary valve replacement (SPVR) to treat pulmonary valve disorders in patients with prior congenital heart surgery. Edwards Sapien 3 valve is a bioprosthesis originally designed for the aortic position but has been used off-label in native right ventricular outflow tract (RVOT). It is currently under clinical trial to get food and drug administration (FDA) approval.
This study is a comparison of the performance of Sapien 3 with surgical bioprosthetics. The in vitro tests result showed Sapien 3 experiences less degree of opening and effective orifice area in pulmonic conditions than surgical valves. The less opening area of the leaflets is a concern after TPVR since it may initiate subclinical leaflet thrombosis and valve stenosis over time. Computational results also showed that the maximum in-plane stress value was higher in Sapien 3 than in surgical valves.
Copyright is held by the author. User is responsible for all copyright compliance.
Received from ProQuest
Shafiei, Mina, "Pulmonary Valve Replacement" (2022). Electronic Theses and Dissertations. 2163.
Engineering, Bioengineering, Biomechanics